Genetics and pharmacogenomics of diffuse gliomas

H. F. Van Thuijl; B. Ylstra; T. Würdinger; D. Van Nieuwenhuizen; J. J. Heimans; P. Wesseling; J. C. Reijneveld

doi:10.1016/j.pharmthera.2012.09.002

Genetics and pharmacogenomics of diffuse gliomas

H. F. Van Thuijl, B. Ylstra, T. Würdinger, D. Van Nieuwenhuizen, J. J. Heimans, P. Wesseling, J. C. Reijneveld

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

4 Citaten (Scopus)

Samenvatting

Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.

Originele taal-2	Engels
Pagina's (van-tot)	78-88
Aantal pagina's	11
Tijdschrift	Pharmacology and Therapeutics
Volume	137
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1016/j.pharmthera.2012.09.002
Status	Gepubliceerd - jan. 2013
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.pharmthera.2012.09.002

Citeer dit

@article{04748cf4a8724142b377f0fe50f3295d,

title = "Genetics and pharmacogenomics of diffuse gliomas",

abstract = "Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.",

keywords = "1p/19q co-deletion, Companion diagnostics, EGFRvIII, Glioma, IDH1, Pharmacogenomics",

author = "{Van Thuijl}, {H. F.} and B. Ylstra and T. W{\"u}rdinger and {Van Nieuwenhuizen}, D. and Heimans, {J. J.} and P. Wesseling and Reijneveld, {J. C.}",

note = "Funding Information: This work is supported by grants of the Dutch Cancer Society ( grant 2009–4470 ), the Edli Foundation and STOPhersentumoren.nl Stichting. Funding Information: Authors J.J. Heimans and J.C. Reijneveld received unrestricted grants from UCB and sanofi-aventis . ",

year = "2013",

month = jan,

doi = "10.1016/j.pharmthera.2012.09.002",

language = "English",

volume = "137",

pages = "78--88",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Genetics and pharmacogenomics of diffuse gliomas

AU - Van Thuijl, H. F.

AU - Ylstra, B.

AU - Würdinger, T.

AU - Van Nieuwenhuizen, D.

AU - Heimans, J. J.

AU - Wesseling, P.

AU - Reijneveld, J. C.

N1 - Funding Information: This work is supported by grants of the Dutch Cancer Society ( grant 2009–4470 ), the Edli Foundation and STOPhersentumoren.nl Stichting. Funding Information: Authors J.J. Heimans and J.C. Reijneveld received unrestricted grants from UCB and sanofi-aventis .

PY - 2013/1

Y1 - 2013/1

N2 - Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.

AB - Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.

KW - 1p/19q co-deletion

KW - Companion diagnostics

KW - EGFRvIII

KW - Glioma

KW - IDH1

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84872300925&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2012.09.002

DO - 10.1016/j.pharmthera.2012.09.002

M3 - Review article

C2 - 22985521

AN - SCOPUS:84872300925

SN - 0163-7258

VL - 137

SP - 78

EP - 88

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

IS - 1

ER -

Genetics and pharmacogenomics of diffuse gliomas

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit